Compare · A vs BRKR
A vs BRKR
Side-by-side comparison of Agilent Technologies Inc. (A) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $43.71B, about 5.0x BRKR ($8.66B).
- Over the past year, A is up 29.8% and BRKR is up 68.0% - BRKR leads by 38.2 points.
- BRKR has hit the wire 19 times in the past 4 weeks while A has been quiet.
- A has more recent analyst coverage (25 ratings vs 22 for BRKR).
- Company
- Agilent Technologies Inc.
- Bruker Corporation
- Price
- $153.54-0.80%
- $57.18+0.56%
- Market cap
- $43.71B
- $8.66B
- 1M return
- +9.24%
- -9.09%
- 1Y return
- +29.80%
- +67.98%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 0
- 19
- Recent ratings
- 25
- 22
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest A
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest BRKR
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)
- PRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax
- PRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)
- PRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)